

Application No. 10/509,533

Restriction Requirement dated June 15, 2007

Response to Restriction Requirement mailed July 10, 2007

Remarks

In response to the Restriction Requirement, the Applicants elect Group I, directed to claims 2-18, and 31-33, drawn to a method of prolonging expression of heterologous gene encoding a prodrug activating enzyme.

In response to the species election, the Applicants elect:

1. p35
2. cytochrome P450, and further cyclophosphamide and other P450 prodrugs including bioreductive agents activated by P450
3. p53
4. Trail
5. P450 enzyme

Applicants reserve the right to file a continuing application or take such other appropriate action as deemed necessary to protect the non-elected inventions. Applicants do not hereby abandon or waive any rights in the non-elected inventions.

In view of the foregoing, Applicants respectfully submit that all claims are in condition for allowance. Early and favorable action is requested.

The Applicants believe no fees are due at this time. However, in the event that any additional fees are required, the Commissioner is authorized to charge Nixon Peabody LLP Deposit Account No. 50-0850.

Respectfully submitted,

Date: July 10, 2007



Ronald I. Eisenstein (Reg. No.: 30,628)

Leena H. Karttunen (Reg. No.: 60,335)

NIXON PEABODY LLP

100 Summer Street

Boston, MA 02110

(617) 345-6054/1367